@msbuller.bsky.social
Reposted
We’re excited to celebrate the FDA approval of revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation. We’re proud of the dedication and innovation that have led to a new therapy now available to patients who need it most.
Learn more: bit.ly/3UYY90B
Blocking the Connection | Dana-Farber Cancer Institute
The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the developmen...
bit.ly
November 25, 2024 at 5:48 PM
We’re excited to celebrate the FDA approval of revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation. We’re proud of the dedication and innovation that have led to a new therapy now available to patients who need it most.
Learn more: bit.ly/3UYY90B
A couple of months ago I moved my cancer blog over to Substack. Last week, I jumped on the BlueSky bandwagon. So of course today I'm bringing those two trendy moves together with my first BlueSky post about my new Substack post. open.substack.com/pub/michaelb...
Why I'm Grateful for Kitchen Towels, Among Other Things
I washed my hands the other day.
open.substack.com
November 25, 2024 at 1:18 AM
A couple of months ago I moved my cancer blog over to Substack. Last week, I jumped on the BlueSky bandwagon. So of course today I'm bringing those two trendy moves together with my first BlueSky post about my new Substack post. open.substack.com/pub/michaelb...